IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ

Kesin Pharma announces FDA approval and availability of Likmez oral suspension

Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing

AstraZeneca to leverage its capabilities to boost US renewable natural gas productivity

Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation

Vaishali Pharma posts Q2 FY24 PAT at Rs. 1.70 Cr

he company posted total income during Q2 FY24 at Rs. 12.86 crore

Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr

European operations' revenue grew 58.4% to Rs 599.7 crore

Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr

The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Pfizer posts Q3 loss as Covid-19 revenues shrink

Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion